Navigation Links
Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
Date:9/17/2008

ent's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described h
'/>"/>
SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
2. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
3. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
4. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
5. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
6. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
7. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
8. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
9. Sinovac to Present at the 2008 UBS Global Life Sciences Conference
10. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
11. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Ill. , ROCHESTER, Minn. ... June 1, 2015 Baxter Ventures, the venture ... the Mayo Clinic and Velocity Pharmaceutical Development, LLC ("VPD") ... Vitesse is a unique collaboration model initiated by Baxter ... protein-based therapeutics in the areas of immunology, hematology, and ...
(Date:6/1/2015)... , June 1, 2015 /CNW/ - Resverlogix Corp. (TSX: ... RVX-208 was presented at the ERA-EDTA Congress in ... "Effects of RVX-208, a First-in-Class Epigenetic BET-Inhibitor, on Key ... and Chronic Kidney Disease (CKD); a Post-hoc Analysis of ... Dr. Kam Kalantar-Zadeh , Professor ...
(Date:6/1/2015)... June 1, 2015   Epic Sciences, Inc. , ... and offerings to personalize and advance the treatment and ... the available credit under its existing credit facility with ... increases the available capacity of the facility from $5 ... by 27 months to April 1, 2019.  The availability ...
(Date:6/1/2015)... 29, 2015 Research and Markets ... of the "2015 Strategies in European ... their offering. This new 273-page ... diagnostic market, including emerging tests, technologies, instrumentation, ... of leading suppliers. Companies Mentioned: ...
Breaking Biology Technology:Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4Epic Sciences Expands Silicon Valley Bank Credit Facility 2Epic Sciences Expands Silicon Valley Bank Credit Facility 3
... Researchers have completed the first thorough, system-level assessment ... of microbes known as Shewanella. Microbes belonging to ... and cleaning up contaminated areas in the environment. ... Institute of Technology, Michigan State University and the ...
... ... , ... The Honolulu-based Pacific Health Research Institute (PHRI) has received $2.8 million in research funding ... a major lung cancer screening study in Hawaii, for two more years. , , , ...
... , , BOTHELL, Wash., ... a leading developer, manufacturer, and marketer of biopreservation tools for ... BloodStor biopreservation media product platform. The product family includes ... as well as other variants for peripheral blood derived stem ...
Cached Biology Technology:Hidden diversity in key environmental cleanup microbes found by systems biology assessment 2Hidden diversity in key environmental cleanup microbes found by systems biology assessment 3Pacific Health Research Institute Awarded $2.8 Million in Research Funding 2Pacific Health Research Institute Awarded $2.8 Million in Research Funding 3BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 2BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 3
(Date:5/21/2015)... , May 21, 2015 The Sync ... of music for health, today announced a collaborative partnership ... The partnership will center on collaboration on original research, ... first step in the collaboration, The Sync Project and ... "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... NEW YORK , May 19, 2015  Technology ... resources both internally and in the cloud. Passwords and ... the use of OTP and standards-based specifications such as ... that the outmoded use of passwords presents for BYOD, ... needs a unified biometric identity protocol. ...
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... discovered that iron-containing nanoparticles being tested for use in ... and interfere with the formation of their signal-transmitting extensions. ... and most life forms and iron oxide nanoparticles were ... professor of materials science at UCSD and senior author ...
... box glowing with fluorescent light, Stacie Grassano pulls out a tube. ... up to her face. Inside, a tree branch is speckled with ... Scott Costa. , Costa brings the branch close to his eye. ... success story." , For some, a fungus success story means ...
... announced that it has added high-density genotyping on ... list of services. Stan Nelson, the principal investigator ... for its user-base of ~10,000 investigators across the ... of the scientific community." , The Consortium ...
Cached Biology News:Widely used iron nanoparticles exhibit toxic effects on neuronal cells 2Widely used iron nanoparticles exhibit toxic effects on neuronal cells 3Fungal factories may save hemlock forests 2Fungal factories may save hemlock forests 3NIH neuroscience microarray consortium launches high-throughput genotyping services 2
Kanamycin is used for selection of resistant bacteria. C18H36N4O11xH2SO4. Contains 10 mg/ml kanamycin (base) utilizing kanamycin sulfate in 0.85% saline....
Request Info...
...
... Agarose-HR High Resolution - ... from 50 to 1000 ... for sizing PCR fragments, ... by restriction enzyme digestion, ...
Biology Products: